Association Between Transferrin Receptor-Ferritin Index and Conventional Measures of Iron Responsiveness in Hemodialysis Patients

American Journal of Kidney Diseases

Volumn 47, Issue 6, 2006, Pages 1036-1044

  Chen, Yen Cheng ^a,b,c   Hung, Szu Chun ^a,b,c   Tarng, Der Cherng ^a,b,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c Immunology Research Center   (Taiwan)

Author keywords

hemodialysis (HD); iron deficiency; recombinant human erythropoietin (rHuEPO); Transferrin receptor ferritin index

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; IRON; IRON POLYMALTOSE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; PRURITUS; VOMITING;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; BIOPSY; BONE MARROW; C-REACTIVE PROTEIN; DIAGNOSTIC TESTS, ROUTINE; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMATOCRIT; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, TRANSFERRIN; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 33646800565     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.02.180     Document Type: Article

References (37)

1. Eschbach J.W., Egrie J.C., Downing M.R., et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of phase I and II clinical trial. N Engl J Med 316 (1987) 73-78
2. Besarab A., Amin N., Ahsan M., et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11 (2000) 530-538
3. Fishbane S., Shapiro W., Dutka P., et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60 (2001) 2406-2411
4. Aronoff G.R. Safety of intravenous iron in clinical practice. Implications for anemia management protocols. J Am Soc Nephrol 15 suppl 2 (2004) S99-S106
5. Burns D.L., and Pomposelli J.J. Toxicity of parenteral iron dextran therapy. Kidney Int Suppl 69 (1999) S119-S124
6. Weiss G., and Goodnough L.T. Medical progress. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
7. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. Update 2000. Am J Kidney Dis 37 suppl 1 (2001) S182-S238
8. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Section II: Targets for anaemia treatment. Nephrol Dial Transplant 19 suppl 2 (2004) Sii6-Sii15
9. Fishbane S., Imbriano L.J., Kowalski E.A., and Maesaka J.K. The evaluation of iron status in patients receiving recombinant human erythropoietin. J Am Soc Nephrol 7 (1996) 2654-2657
10. Tarng D.C., Huang T.P., and Chen T.W. Erythropoietin hyporesponsiveness. From iron deficiency to iron overload. Kidney Int Suppl 69 (2000) S107-S118
11. Shih Y.J., Baynes R.D., Hudson B.G., et al. Serum transferring receptor is a truncated form of tissue receptor. J Biol Chem 265 (1990) 19077-19081
12. Tarng D.C., and Huang T.P. Determinants of circulating soluble transferring receptor level in chronic haemodialysis patients. Nephrol Dial Transplant 17 (2002) 1063-1069
13. Tarng D.C., Hung S.C., and Huang T.P. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients. J Am Soc Nephrol 15 (2004) 2486-2493
14. Tonbul H.Z., Kaya H., Selcuk Y., et al. The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in hemodialysis patients. Int Urol Nephrol 30 (1998) 645-651
15. Gunnell J., Yeun J.Y., Depner T.A., and Kaysen G.A. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33 (1999) 63-72
16. Bovy C., Tsobo C., Crapanzano L., et al. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 56 (1999) 1113-1119
17. Lorenzo J.D., Rodríguez M.M., Martín S.S., and Romo J.M. Assessment of erythropoiesis activity during hemodialysis therapy by soluble transferrin receptor levels and ferrokinetic measurements. Am J Kidney Dis 37 (2001) 550-556
18. Chiang W.C., Tsai T.J., Chen Y.M., et al. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol 58 (2002) 363-369
19. Punnonen K., Irjala K., and Rajamaki A. Serum transferring receptor, ferritin and TfR-F index in identification of latent iron deficiency. Eur J Haematol 60 (1998) 135-137
20. Cermak J. Transferrin receptor-ferritin index. A useful parameter in differential diagnosis of iron deficiency and hyperplasic erythropoiesis. Eur J Haematol 61 (1998) 210-212
21. Thomas C., and Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48 (2002) 1066-1076
22. Punnonen K., Irjala K., and Rajamaki A. Serum transferring receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 89 (1997) 1052-1057
23. Rimon E., Levy S., Sapir A., et al. Diagnosis of iron deficiency anemia in the elderly by transferrin receptor-ferritin index. Arch Intern Med 162 (2002) 445-449
24. Van Wyck D.B., Danielson B.G., and Aronoff G.R. Making sense. A scientific approach to intravenous iron therapy. J Am Soc Nephrol 15 suppl 2 (2004) S91-S92
25. Fishbane S., Frei G.L., and Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26 (1995) 41-46
26. Macdougall I.C., Tucker B., Thompson J., et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50 (1996) 1694-1699
27. Tarng D.C., Chen T.W., and Huang T.P. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15 (1995) 230-237
28. van Zyl-Smit R., and Halkett J.A. Experience with the use of an iron polymaltose (dextrin) complex given by single total dose infusion to stable chronic hemodialysis patients. Nephron 92 (2002) 316-323
29. Granolleras C., Zein A., Oulès R., et al. Continuous administration of intravenous iron during hemodialysis. Nephrol Dial Transplant 12 (1997) 1007-1008
30. Kalantar-Zadeh K., Höffken B., Wünsch H., et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26 (1995) 292-299
31. Tessitore N., Solero G.P., Lippi G., et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16 (2001) 1416-1423
32. Richardson D., Bartlett C., and Will E.J. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis 38 (2001) 109-117
33. Mittman N., Sreedhara R., Mushnick R., et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 30 (1997) 912-922
34. Chuang C.L., Liu R.S., Wei Y.H., Huang T.P., and Tarng D.C. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 318 (2003) 370-377
35. Madore F., Lowrie E.G., Brugnara C., et al. Anemia in hemodialysis patients. Variables affecting this outcome predictor. J Am Soc Nephrol 8 (1997) 1921-1929
36. Kalantar-Zadeh K., Ikizler T.A., Block G., Avram M.M., and Kopple J.D. Malnutrition-inflammation complex syndrome in dialysis patients. Causes and consequences. Am J Kidney Dis 42 (2003) 864-881
37. Tonelli M., Blake P.G., and Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J 47 (2001) 82-85